Sign In
Buy IRTC
$117.17
-1.91 (-1.60%)
At Close: Jul 31, 2026
New sell-side coverage - healthcare
12:37pm, Thursday, 05'th Mar 2020
10X Genomics (NASDAQ:TXG) initiated with Buy rating and $95 (23% upside) price target at Guggenheim.Abbott (NYSE:ABT) initiated with Buy rating at Citigroup. Shares down 1% premarket.Alcon (NYSE:ALC
Wearable health tech startup pumps $145M into completing defibrillator patch product
09:21pm, Wednesday, 04'th Mar 2020
Element Science was valued at $230 million when it scored its Series A round in August, more than 10 times its previous valuation. The San Francisco medical device and information technology company i
Element Science Raises $145.6 million Series C Financing to Advance Next-Generation Digital Wearable Platform
03:26pm, Tuesday, 03'rd Mar 2020
Press Release Element Science, an innovative health technology company pioneering a next-generation digital wearable platform focused on high-risk cardiovascular patients transitioning from the hospit
Element Science Raises $145.6 million Series C Financing to Advance Next-Generation Digital Wearable Platform
03:00pm, Tuesday, 03'rd Mar 2020
Element Science, an innovative health technology company pioneering a next-generation digital wearable platform focused on high-risk cardiovascular patients transitioning from the hospital-to-home, an
Irhythm Technologies Inc (NASDAQ:IRTC) Expected to Post Quarterly Sales of $63.84 Million
09:16am, Tuesday, 03'rd Mar 2020
Equities analysts predict that Irhythm Technologies Inc (NASDAQ:IRTC) will announce $63.84 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided
Aviva PLC Buys New Stake in Irhythm Technologies Inc (NASDAQ:IRTC)
10:28am, Monday, 02'nd Mar 2020
Aviva PLC bought a new stake in Irhythm Technologies Inc (NASDAQ:IRTC) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 26
iRhythm Technologies, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
01:34pm, Sunday, 01'st Mar 2020
iRhythm Technologies, Inc. (NASDAQ:IRTC) came out with its annual results last week, and we wanted to see how the...
Is iRhythm Technologies (NASDAQ:IRTC) Using Too Much Debt?
12:24pm, Sunday, 01'st Mar 2020
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Canaccord Genuity Increases Irhythm Technologies (NASDAQ:IRTC) Price Target to $112.00
10:54am, Sunday, 01'st Mar 2020
Irhythm Technologies (NASDAQ:IRTC) had its price target raised by equities research analysts at Canaccord Genuity from $107.00 to $112.00 in a research note issued on Friday, BenzingaRatingsTable repo
Irhythm Technologies (NASDAQ:IRTC) Trading Up 8.2% on Analyst Upgrade
07:16am, Saturday, 29'th Feb 2020
Irhythm Technologies Inc (NASDAQ:IRTC) was up 8.2% on Friday after Canaccord Genuity raised their price target on the stock from $107.00 to $112.00. Canaccord Genuity currently has a buy rating on the
iRhythm Technologies, Inc. Common Stock (IRTC) Q4 2019 Earnings Call Transcript
02:01pm, Friday, 28'th Feb 2020
IRTC earnings call for the period ending December 31, 2019.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (IRTC), Madrigal Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Nektar Therapeutics (NKTR)
04:39am, Friday, 28'th Feb 2020
Analysts fell to the sidelines weighing in on Irhythm Technologies (IRTC) and Nektar Therapeutics (NKTR) with neutral ratings, indicating that the experts
iRhythm Technologies' (IRTC) CEO Kevin King on Q4 2019 Results - Earnings Call Transcript
03:24am, Friday, 28'th Feb 2020
iRhythm Technologies, Inc. (NASDAQ:IRTC) Q4 2019 Earnings Conference Call February 27, 2020, 04:30 PM ET Company Participants Leigh Salvo - IR Kevin King - Pres
IRHYTHM TECH (IRTC) Reports Q4 Loss, Tops Revenue Estimates
10:25pm, Thursday, 27'th Feb 2020
IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of -25.00% and 0.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
